The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis
Diana Sherifali, Kara Nerenberg, Eleanor Pullenayegum, Ji Emmy Cheng, Hertzel C Gerstein, Diana Sherifali, Kara Nerenberg, Eleanor Pullenayegum, Ji Emmy Cheng, Hertzel C Gerstein
Abstract
Objective: Previous reviews of the effect of oral antidiabetic (OAD) agents on A1C levels summarized studies with varying designs and methodological approaches. Using predetermined methodological criteria, we evaluated the effect of OAD agents on A1C levels.
Research design and methods: The Excerpta Medica (EMBASE), the Medical Literature Analysis and Retrieval System Online (MEDLINE), and the Cochrane Central Register of Controlled Trials databases were searched from 1980 through May 2008. Reference lists from systematic reviews, meta-analyses, and clinical practice guidelines were also reviewed. Two evaluators independently selected and reviewed eligible studies.
Results: A total of 61 trials reporting 103 comparisons met the selection criteria, which included 26,367 study participants, 15,760 randomized to an intervention drug(s), and 10,607 randomized to placebo. Most OAD agents lowered A1C levels by 0.5-1.25%, whereas thiazolidinediones and sulfonylureas lowered A1C levels by approximately 1.0-1.25%. By meta-regression, a 1% higher baseline A1C level predicted a 0.5 (95% CI 0.1-0.9) greater reduction in A1C levels after 6 months of OAD agent therapy. No clear effect of diabetes duration on the change in A1C with therapy was noted.
Conclusions: The benefit of initiating an OAD agent is most apparent within the first 4 to 6 months, with A1C levels unlikely to fall more than 1.5% on average. Pretreated A1C levels have a modest effect on the fall of A1C levels in response to treatment.
Figures
References
- Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–1972
- Canadian Diabetes Association Clinical Practice Guideline Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32:S1–S201
- Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D: Metformin therapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;CD002966. [PMID:16034881]
- Chilcott J, Tappenden P, Jones ML, Wight JP: A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001;23:1792–1823
- van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154–163
- Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–372
- Garlick RL, Mazer JS, Higgins PJ, Bunn HF: Characterization of glycosylated hemoglobins: relevance to monitoring of diabetic control and analysis of other proteins. J Clin Invest 1983;71:1062–1072
- Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F: Meta-analyses in medical research. Wiley, Rexdale, Ontario, Canada, 2000.
- Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE: Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006;29:2137–2139
Source: PubMed